Welcome to our dedicated page for Bionomics news (Ticker: BNOX), a resource for investors and traders seeking the latest updates and insights on Bionomics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bionomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bionomics's position in the market.
Bionomics Limited (Nasdaq: BNOX | ASX: BNO), a clinical-stage biopharmaceutical company, announced participation in three upcoming investor conferences. Dr. Errol De Souza, Executive Chairman, will present at:
- Citibank Biotech’s Mood Disorders/Mental Health Panel on May 18, 2022, at 11:00 am ET.
- Berenberg Capital Markets Emerging Biotech Conference on May 19, 2022.
- H.C. Wainwright Global Investment Conference from May 23-26, 2022.
Audio webcasts will be available on Bionomics’ website during these events.
Novamind Inc. has been selected to host the PREVAIL Trial, a phase II clinical study focusing on the treatment of social anxiety disorder (SAD). Sponsored by Bionomics Limited (NASDAQ:BNOX), the trial will investigate the safety and efficacy of BNC210 compared to a placebo. SAD affects nearly 15 million U.S. adults, and existing treatments often come with adverse effects. The study aims to provide new insights into alternative treatment options for this common issue. Previous studies by Novamind have also focused on PTSD using BNC210.
Bionomics Limited (ASX: BNO, Nasdaq: BNOX) reported its half-year results for the period ending December 31, 2021. This phase is characterized by significant pipeline advancements, including the initiation of Phase 2b clinical trials for BNC210 focused on PTSD and SAD. The company raised US$23.04 million from an IPO, enhancing its financial position with a cash balance of A$40.35 million. Strategic partnerships continue to develop, particularly with Merck & Co. for Alzheimer's treatments. The report underscores a commitment to creating long-term shareholder value.
Bionomics Limited (Nasdaq: BNOX, ASX: BNO) will ring the Nasdaq Closing Bell remotely on January 14, 2022. The ceremony will feature Dr Errol De Souza, Executive Chairman, and the company team. The live stream can be accessed through the Nasdaq website. Bionomics is focused on developing allosteric ion channel modulators for central nervous system disorders, with its lead candidate, BNC210, targeting Social Anxiety Disorder and PTSD. The company has a partnership with Merck for cognitive treatment trials in Alzheimer's disease.
Bionomics Limited (NASDAQ:BNOX) participated in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. Dr. Errol De Souza, Executive Chairman, highlighted BNC210, a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor. The drug is in development for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. BNC210 has received Fast Track designation from the FDA for both conditions, marking a significant step in its clinical journey.
Bionomics Limited has initiated its Phase 2 clinical trial (PREVAIL Study) for BNC210, targeting Social Anxiety Disorder (SAD). The trial aims to evaluate the efficacy of BNC210 as an acute treatment, with topline results expected by late 2022. BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, has received FDA Fast Track designation for both SAD and PTSD. The study includes 15-20 U.S. clinical sites and will assess treatment impact on anxiety levels using various measurement scales.